Heron Therapeutics | HRTX - Pre Tax Profit


Heron Therapeutics reported $-4.85M in Pre-Tax Profit for its fiscal quarter ending in September of 2024.





Pre Tax Profit Change Date
ALKERMES USD 100.74M 4.1M Sep/2025
Alnylam Pharmaceuticals USD 238.97M 274.33M Sep/2025
Amarin USD -8.12M 5.34M Sep/2025
ANI Pharmaceuticals USD 49.52M 39M Sep/2025
Anika Therapeutics USD -3.87M 32.43M Mar/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
Eisai JPY 22B 7.47B Dec/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Insmed USD -368.7M 48.26M Sep/2025
Ligand Pharmaceuticals USD 141.14M 102M Sep/2025
Merck USD 6.74B 22M Sep/2025
Nektar Therapeutics USD -37.05M 15.27M Sep/2024
Neurocrine Biosciences USD 291.8M 132.3M Sep/2025
Omeros USD -65.12M 21.27M Jun/2024
Pacira USD -1.93M 10.63M Jun/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Surmodics USD -7.51M 1.69M Sep/2024
Ultragenyx Pharmaceutical USD -179.54M 65.54M Sep/2025
Veracyte USD 18.89M 17.64M Sep/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025